BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16569769)

  • 1. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.
    Zhang Z; Zhang M; Garmestani K; Talanov VS; Plascjak PS; Beck B; Goldman C; Brechbiel MW; Waldmann TA
    Blood; 2006 Aug; 108(3):1007-12. PubMed ID: 16569769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
    Chen J; Zhang M; Ju W; Waldmann TA
    Blood; 2009 Feb; 113(6):1287-93. PubMed ID: 18948574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
    Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.
    Zhang M; Yao Z; Garmestani K; Yu S; Goldman CK; Paik CH; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2009 Jun; 24(3):303-9. PubMed ID: 19538052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody.
    Zhang M; Zhang Z; Goldman CK; Janik J; Waldmann TA
    Blood; 2005 Feb; 105(3):1231-6. PubMed ID: 15383455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia.
    Zhang M; Yao Z; Zhang Z; Garmestani K; Talanov VS; Plascjak PS; Yu S; Kim HS; Goldman CK; Paik CH; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Res; 2006 Aug; 66(16):8227-32. PubMed ID: 16912202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507.
    Zhang Z; Zhang M; Ravetch JV; Goldman C; Waldmann TA
    Blood; 2003 Jul; 102(1):284-8. PubMed ID: 12649132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
    Berkowitz JL; Janik JE; Stewart DM; Jaffe ES; Stetler-Stevenson M; Shih JH; Fleisher TA; Turner M; Urquhart NE; Wharfe GH; Figg WD; Peer CJ; Goldman CK; Waldmann TA; Morris JC
    Clin Immunol; 2014 Dec; 155(2):176-87. PubMed ID: 25267440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
    Zhang M; Yao Z; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Janik J; Brechbiel MW; Waldmann TA
    Blood; 2006 Jul; 108(2):705-10. PubMed ID: 16551968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac.
    Rubin LA; Kurman CC; Biddison WE; Goldman ND; Nelson DL
    Hybridoma; 1985; 4(2):91-102. PubMed ID: 2408992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.
    Kobayashi H; Sun BF; Han ES; Kim MK; Le N; Wang QC; Nelson DL; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
    Jpn J Cancer Res; 1998 Apr; 89(4):436-44. PubMed ID: 9617350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab.
    Egan CA; Brown M; White JD; Yancey KB
    Clin Immunol; 2001 Nov; 101(2):146-51. PubMed ID: 11683573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
    Zhang M; Yao Z; Garmestani K; Axworthy DB; Zhang Z; Mallett RW; Theodore LJ; Goldman CK; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Blood; 2002 Jul; 100(1):208-16. PubMed ID: 12070029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
    Chen J; Pise-Masison CA; Shih JH; Morris JC; Janik JE; Conlon KC; Keating A; Waldmann TA
    Blood; 2013 Mar; 121(11):2029-37. PubMed ID: 23321252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
    Waldmann TA
    J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
    Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
    Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
    Praditpornsilpa K; Avihingsanon Y; Kupatawintu P; Songpanich S; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; O-Charoen R; Tungsanga K
    Transplant Proc; 2004 Mar; 36(2 Suppl):487S-491S. PubMed ID: 15041394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.